Induction of heat shock proteins prevents the arrhythmogenic substrate for atrial fibrillation

International Journal of Hyperthermia

Volumn 25, Issue 8, 2009, Pages 641-646

  Takahashi, Naohiko ^a   Wakisaka, O ^b   Yoshimatsu, H ^b   Saikawa, T ^a  

^a OITA UNIVERSITY   (Japan)

^b OITA UNIVERSITY   (Japan)

Author keywords

Atrial fibrillation; Atrial fibrosis; Atrial refractory period

Indexed keywords

ANGIOTENSIN II; CALCIUM CHANNEL L TYPE; CANDESARTAN; ENALAPRIL; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 72; TEPRENONE; VALSARTAN;

ACUTE CORONARY SYNDROME; ARRHYTHMOGENESIS; HEART ATRIUM CONDUCTION; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART MUSCLE FIBROSIS; HEART MUSCLE REFRACTORY PERIOD; HEART PACING; HEART PROTECTION; HUMAN; HYPERTHERMIC THERAPY; NONHUMAN; OPEN HEART SURGERY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

ANIMALS; ATRIAL FIBRILLATION; DITERPENES; DOGS; FEVER; FIBROSIS; HEART ATRIA; HSP27 HEAT-SHOCK PROTEINS; HSP72 HEAT-SHOCK PROTEINS; HUMANS;

EID: 73649134024     PISSN: 02656736     EISSN: 14645157     Source Type: Journal    
DOI: 10.3109/02656730903070949     Document Type: Review

References (37)

1. Rich MW. Epidemiology of atrial fibrillation. J Interv Card Electrophysiol 2009;25:3-8.
2. Naccarelli GV, Gonzalez MD. Atrial fibrillation and the expanding role of catheter ablation: Do antiarrhythmic drugs have a future? J Cardiovasc Pharmacol 2008;52:203-209.
3. Burstein B, Nattel S. Atrial fibrosis: Mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol 2008; 51:802-809.
4. Brundel BJ, Ke L, Dijkhuis AJ, Qi X, Shiroshita-Takeshita A, Nattel S, Henning RH, Kampinga HH. Heat shock proteins as molecular targets for intervention in atrial fibrillation. Cardiovasc Res 2008;78:422-428.
5. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995;92:1954-1968.
6. Bosch RF, Zeng X, Grammer JB, Popovic K, Mewis C, Kühlkamp V. Ionic mechanisms of electrical remodeling in human atrial fibrillation. Cardiovasc Res 1999;44:121-131.
7. Yue L, Feng J, Gaspo R, Li GR, Wang Z, Nattel S. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res 1997;81:512-525.
8. Gaspo R, Bosch RF, Talajic M, Nattel S. Functional mechanisms underlying tachycardia-induced sustained atrial fibrillation in a chronic dog model. Circulation 1997;96: 4027-4035.
9. Sun H, Chartier D, Leblanc N, Nattel S. Intracellular calcium changes and tachycardia-induced contractile dysfunction in canine atrial myocytes. Cardiovasc Res 2001;49:751-761.
10. Yue L, Melnyk P, Gaspo R, Wang Z, Nattel S. Molecular mechanisms underlying ionic remodeling in a dog model of atrial fibrillation. Circ Res 1999;84:776-784.
11. Brundel BJ, Van Gelder IC, Henning RH, Tieleman RG, Tuinenburg AE, Wietses M, Grandjean JG, Van Gilst WH, Crijns HJ. Ion channel remodeling is related to intraoperative atrial effective refractory periods in patients with paroxysmal and persistent atrial fibrillation. Circulation 2001;103: 684-690.
12. Nattel S, Li D. Ionic remodeling in the heart: Pathophysiological significance and new therapeutic opportunities for atrial fibrillation. Circ Res 2000;87:440-447.
13. Shiroshita-Takeshita A, Brundel BJ, Nattel S. Atrial fibrillation: Basic mechanisms, remodeling and triggers. J Interv Card Electrophysiol 2005;13:181-193. (Pubitemid 41372065)
14. Kostin S, Klein G, Szalay Z, Hein S, Bauer EP, Schaper J. Structural correlate of atrial fibrillation in human patients. Cardiovasc Res 2002;54:361-379. (Pubitemid 34327915)
15. Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003;41:2197-2204.
16. Goette A, Staack T, Röcken C, Arndt M, Geller JC, Huth C, Ansorge S, Klein HU, Lendeckel U. Increased expression of extracellular signal-regulated kinase and angiotensinconverting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000;35:1669-1677.
17. Goette A, Arndt M, Röcken C, Spiess A, Staack T, Geller JC, Huth C, Ansorge S, Klein HU, Lendeckel U. Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation 2000;101:2678-2681.
18. Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, Guerra PG, Ducharme A. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: Insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003;107: 2926-2931. (Pubitemid 36736634)
19. Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, Michelson EL, McMurray JJ, Olsson L, Rouleau JL, et al. CHARM Investigators. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006;152:86-92.
20. Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, Glazer R, Masson S, Cerè E, Tognoni G, Cohn JN. Val-HeFT Investigators. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005;149:548-557.
21. Aksnes TA, Flaa A, Strand A, Kjeldsen SE. Prevention of new-onset atrial fibrillation and its predictors with angiotensin II-receptor blockers in the treatment of hypertension and heart failure. J Hypertens 2007;25:15-23.
22. Brundel BJ, Henning RH, Ke L, van Gelder IC, Crijns HJ, Kampinga HH. Heat shock protein upregulation protects against pacing-induced myolysis in HL-1 atrial myocytes and in human atrial fibrillation. J Mol Cell Cardiol 2006;41:555-562.
23. Brundel BJ, Shiroshita-Takeshita A, Qi X, Yeh YH, Chartier D, van Gelder IC, Henning RH, Kampinga HH, Nattel S. Induction of heat shock response protects the heart against atrial fibrillation. Circ Res 2006;99:1394-1402.
24. Wakisaka O, Takahashi N, Shinohara T, Ooie T, Nakagawa M, Yonemochi H, Hara M, Shimada T, Saikawa T, Yoshimatsu H. Hyperthermia treatment prevents angiotensin II-mediated atrial fibrosis and fibrillation via induction of heat-shock protein 72. J Mol Cell Cardiol 2007;43:616-626.
25. Sakabe M, Shiroshita-Takeshita A, Maguy A, Brundel BJ, Fujiki A, Inoue H, Nattel S. Effects of a heat shock protein inducer on the atrial fibrillation substrate caused by acute atrial ischaemia. Cardiovasc Res 2008;78:63-70.
26. Sinno H, Derakhchan K, Libersan D, Merhi Y, Leung TK, Nattel S. Atrial ischemia promotes atrial fibrillation in dogs. Circulation 2003;107:1930-1936.
27. Jayakumar J, Suzuki K, Sammut IA, Smolenski RT, Khan M, Latif N, Abunasra H, Murtuza B, Amrani M, Yacoub MH. Heat shock protein 70 gene transfection protects mitochondrial and ventricular function against ischemia-reperfusion injury. Circulation 2001;104:SI303-SI307.
28. Ooie T, Takahashi N, Saikawa T, Nawata T, Arikawa M, Yamanaka K, Hara M, Shimada T, Sakata T. Single oral dose of geranylgeranylacetone induces heat-shock protein 72 and renders protection against ischemia/reperfusion injury in rat heart. Circulation 2001;104:1837-1843.
29. Yamanaka K, Takahashi N, Ooie T, Kaneda K, Yoshimatsu H, Saikawa T. Role of protein kinase C in geranylgeranylacetoneinduced expression of heat-shock protein 72 and cardioprotection in the rat heart. J Mol Cell Cardiol 2003;35:785-794.
30. Shinohara T, Takahashi N, Ooie T, Ichinose M, Hara M, Yonemochi H, Saikawa T, Yoshimatsu H. Estrogen inhibits hyperthermia-induced expression of heat-shock protein 72 and cardioprotection against ischemia/reperfusion injury in female rat heart. J Mol Cell Cardiol 2004;37: 1053-1061.
31. Shinohara T, Takahashi N, Kohno H, Yamanaka K, Ooie T, Wakisaka O, Murozono Y, Taniguchi Y, Torigoe Y, Hara M, et al. Mitochondria are targets for geranylgeranylacetoneinduced cardioprotection against ischemia-reperfusion in the rat heart. Am J Physiol Heart Circ Physiol 2007;293: H1892-H1899.
32. Shinohara T, Takahashi N, Ooie T, Hara M, Shigematsu S, Nakagawa M, Yonemochi H, Saikawa T, Yoshimatsu H. Phosphatidylinositol 3-kinase-dependent activation of AKT, an essential signal for hyperthermia-induced heat-shock protein 72, is attenuated in streptozotocin-induced diabetic heart. Diabetes 2006;55:1307-1315.
33. Taniguchi Y, Ooie T, Takahashi N, Shinohara T, Nakagawa M, Yonemochi H, Hara M, Yoshimatsu H, Saikawa T. Pioglitazone but not glibenclamide improves cardiac expression of heat shock protein 72 and tolerance against ischemia/ reperfusion injury in the heredity insulin-resistant rat. Diabetes 2006;55:2371-2378.
34. Frost L, Mølgaard H, Christiansen EH, Hjortholm K, Paulsen PK, Thomsen PE. Atrial fibrillation and flutter after coronary artery bypass surgery: Epidemiology, risk factors and preventive trials. Int J Cardiol 1992;36:253-261.
35. Goodman S, Weiss Y, Weissman C. Update on cardiac arrhythmias in the ICU. Curr Opin Crit Care 2008;14:549-554.
36. St Rammos K, Koullias GJ, Hassan MO, Argyrakis NP, Voucharas CG, Scarupa SJ, Cowte TG. Low preoperative Hsp70 atrial myocardial levels correlate significantly with high incidence of postoperative atrial fibrillation after cardiac surgery. Cardiovasc Sur 2002;10:228-232.
37. Mandal K, Torsney E, Poloniecki J, Camm AJ, Xu Q, Jahangiri M. Association of high intracellular, but not serum, heat shock protein 70 with postoperative atrial fibrillation. Ann Thorac Surg 2005;79:865-871.